Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikole Varhegyi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Trials (London, England)|June 27, 2017
A web application for evaluating Phase I methods using a non-parametric optimal benchmarkNolan A Wages, Nikole Varhegyi
Computer Methods and Programs in Biomedicine|July 23, 2013
pocrm: an R-package for phase I trials of combinations of agentsNolan A Wages, Nikole Varhegyi
The American Journal of Hospice & Palliative Care|August 31, 2014
An interprofessional workshop for students to improve communication and collaboration skills in end-of-life careJeanne M Erickson, Leslie Blackhall, Valentina Brashers, et al.
International Journal of Radiation Oncology, Biology, Physics|November 23, 2020
Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 TrialNolan A Wages, Jason C Sanders, Amy Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaPatrick M Dillon, Gina R Petroni, Bethany J Horton, et al.
Journal for Immunotherapy of Cancer|June 29, 2019
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patientsMarit M Melssen, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|May 10, 2020
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanomaVictor H Engelhard, Rebecca C Obeng, Kara L Cummings, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|June 27, 2017
A web application for evaluating Phase I methods using a non-parametric optimal benchmarkNolan A Wages, Nikole Varhegyi
Computer Methods and Programs in Biomedicine|July 23, 2013
pocrm: an R-package for phase I trials of combinations of agentsNolan A Wages, Nikole Varhegyi
The American Journal of Hospice & Palliative Care|August 31, 2014
An interprofessional workshop for students to improve communication and collaboration skills in end-of-life careJeanne M Erickson, Leslie Blackhall, Valentina Brashers, et al.
International Journal of Radiation Oncology, Biology, Physics|November 23, 2020
Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 TrialNolan A Wages, Jason C Sanders, Amy Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaPatrick M Dillon, Gina R Petroni, Bethany J Horton, et al.
Journal for Immunotherapy of Cancer|June 29, 2019
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patientsMarit M Melssen, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|May 10, 2020
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanomaVictor H Engelhard, Rebecca C Obeng, Kara L Cummings, et al.
Pageof 1